CSBR

Business Context and Reporting Period

Company: Champions Oncology, Inc. (CSBR)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended July 31, 2025
Business Overview: The Company is a technology-enabled research organization providing drug discovery and development services. Its core offering is the TumorGraft Technology Platform, which utilizes Patient Derived Xenograft (PDX) models to predict oncology drug efficacy. The Company operates in a single reportable segment and is classified as a smaller reporting company.

Key Financial Metrics

Note: Working capital is calculated as Total Current Assets ($21,014) minus Total Current Liabilities ($22,698).

Material Changes vs. Prior Period

• Revenue: Oncology revenue decreased slightly by 0.5% ($66,000) to $13.995 million. While Pharmacology services revenue increased slightly, this was offset by a significant decline in "Other TOS Revenue" (flow cytometry services), which dropped approximately $540,000 due to a strategic de-emphasis on that business unit.
• Profitability: The Company reported a net loss of $466,000, a reversal from a net income of $1.313 million in the prior year. Operating income turned negative at $(527,000) compared to $1.329 million previously.
• Expenses:
  • Cost of Oncology Revenue: Increased 13.1% to $7.995 million, primarily due to higher outsourced lab services for radiolabeling.
  • Research and Development (R&D): Increased 43.2% to $2.082 million, driven by increased investment in the data licensing platform and the Corellia subsidiary.
  • Sales and Marketing: Increased 10.5% to $1.855 million to support data license business growth.
• Liquidity: Cash and cash equivalents increased significantly to $10.325 million from $2.892 million in the prior year, supported by strong operating cash flow of $600,000.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes cash on hand ($10.3 million) combined with expected operating cash flows is adequate to fund operations through at least October 2026. The Company currently has negative working capital of approximately $1.7 million.
• Strategic Focus: The Company is de-emphasizing flow cytometry services while increasing investment in its data licensing platform and Corellia AI subsidiary for target discovery.
• Capital Resources: The Company has a share repurchase program authorizing up to $5.0 million; as of July 31, 2025, approximately $4.3 million remains available. No shares were repurchased in the current quarter.
• Risks: As a smaller reporting company, the filing does not include updated risk factors but references the 2025 Annual Report. General risks include economic uncertainty, supply chain disruptions, and the inability to raise additional capital if required.
• Unusual Items: A loss on disposal of equipment of $20,000 was recorded in the current quarter.

Investor Verification Checklist

• Cash Runway: Verify the sustainability of the $10.3 million cash balance against the negative working capital position and the timeline to October 2026.
• Revenue Mix Shift: Confirm the strategic rationale and long-term impact of the $540,000 decline in flow cytometry revenue versus the growth in data licensing.
• Cost Management: Monitor the trend of "Cost of Oncology Revenue," specifically the outsourced radiolabeling costs, to ensure they decrease as planned when work is migrated in-house.
• R&D Efficiency: Assess the return on the 43% increase in R&D spending, particularly regarding the Corellia subsidiary and data platform investments.
• Deferred Revenue: Review the $14.43 million deferred revenue balance to understand future revenue recognition visibility.